Literature DB >> 326400

Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report.

L K Kvols, R T Eagan, R P Myers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 326400

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  3 in total

1.  Prostatic cancer: the response to treatment dilemma.

Authors: 
Journal:  Br Med J       Date:  1980-03-29

2.  Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer.

Authors:  D C Smith; D I Jodrell; M J Egorin; R M Ambinder; E G Zuhowski; W Kreis; P G Ellis; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 3.  Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group.

Authors:  Eric Winquist; Tricia Waldron; Scott Berry; D Scott Ernst; Sébastien Hotte; Himu Lukka
Journal:  BMC Cancer       Date:  2006-05-02       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.